pharmaceutical consulting

Sylvie Tendler & Associates has assisted numerous pharmaceutical companies in addressing critical challenges. Whether assessing the value of in-line/ pipeline Oncology agents as part of a due diligence, or go-to market strategies, our rigorous analysis improves outcomes.

due diligence

Product line analysis as part of purchaser due diligence team. Qualifying and quantifying in-line and pipeline pharmaceutical products to determine true portfolio value. Market assessment as it relates to market opportunity. Use of multi-data sources in order to determine current and future product value with emphasis on competitive landscape, regulatory environment, and pricing options.

market entry

Oh Canada!---incredible country, great people, but a complex healthcare system. Socialized medicine,  growing private sector, federal approval, provincial approvals, formulary coverage, hospital formularies---the list is endless and changes as you cross provincial lines. Equivalent to filing for product approval in 10 countries--tough enough for us locals, even harder for those venturing to enter the market. Here's the offering--

Market entry strategies for foreign companies. Evaluate all entry options including licensing, partnering, and acquisition opportunities. Maximize entry, determine level of investment and risk mitigation strategies.  Preparation of market materials for Health Canada pre-submission meetings. Market related data for New Drug Submissions (NDS) to Health Canada.

equity financing

Market research in preparation for equity financing. Assist in the design of overall value proposition. Aligning marketing to financial projections for submission of investor prospectus.